Report copyright - AKT Inhibition Promotes Nonautonomous Cancer Cell SurvivalAkti-1/2, MK-2206), at a subtherapeutic dose (i.e., which only partially suppresses AKT signaling by about 80–90%), dramati-cally
Please pass captcha verification before submit form